Fig. 5From: Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccineAntibody correlation analysis. A Anti-S IgG titer correlation with anti-RBD antibody levels. B Anti-RBD IgG titer correlation with neutralizing antibody levels. The best-fit line, R2 and p value for each panel were determined by a Pearson test using log-transformed dataBack to article page